Navigation Links
Halt Medical Announces CMS Assignment of Ambulatory Payment Classification for RF Ablation of Uterine Fibroids
Date:12/2/2013

LIVERMORE, Calif., Dec. 2, 2013 /PRNewswire/ -- Halt Medical is pleased to announce that the Centers for Medicare and Medicaid Services (CMS) has established a new Ambulatory Payment Classification (APC) for Radiofrequency (RF) Ablation of Uterine Fibroids. The APC 174 carries a reimbursement rate of $8,593.40 for the single-use handpiece and the hospital's other operating costs related to the procedure. The physician reports services under the newly created CPT code – 0336T, and is reimbursed separately. The APC and CPT codes will become effective January 1, 2014. 

(Logo: http://photos.prnewswire.com/prnh/20131202/LA26268LOGO)

"The assignment of an APC recognizes that RF ablation with the Acessa System is an important option for women suffering from uterine fibroids," said Jayne A. Little, Halt Medical's VP of Global Healthcare Economics. Jeffrey M. Cohen, CEO of Halt Medical added, "Today's decision further validates the Acessa Procedure in the treatment algorithm of symptomatic uterine fibroids." David J. Levine, MD has shared, "By recognizing this procedure and establishing a fee schedule, I'm able to continue to offer Acessa as a viable treatment option for my patients. They're the real winners here."

The Acessa Procedure is a minimally invasive laparoscopic procedure that delivers radiofrequency energy to destroy the fibroids. After treatment, the fibroid is re-absorbed by the surrounding tissue. Acessa allows the surgeon to treat only the fibroids, while preserving normal function of the uterus. Patients typically go home the same day with little pain, and enjoy a rapid return to normal activities. The Acessa System is now available at leading medical centers throughout the U.S.

About Halt Medical, Inc.

Founded in 2004, Halt Medical is a medical device innovator focused on establishing a new standard of care for women with symptomatic uterine fibroids. The Company has developed and launched the Acessa System and Procedure, using radiofrequency energy to destroy uterine fibroids. The results of both U.S. and international trials have led to the clearance of the product by the FDA for use in percutaneous, laparoscopic coagulation and ablation of soft tissue, including treatment of symptomatic uterine fibroids under laparoscopic ultrasound guidance. The Acessa System also has regulatory approval to treat symptomatic uterine fibroids in the European Union, Canada, and Mexico. The Company is located in Brentwood, CA. For information about the Acessa System, please visit www.haltmedical.com. To connect with Halt Medical on Facebook visit www.facebook.com/acessasystem or on Twitter at www.twitter.com/acessasystem.  

WEBSITE:  http://www.haltmedical.com  


'/>"/>
SOURCE Halt Medical, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Lung Cancer Alliance Congratulates 75 Medical Centers For Moving Swiftly And Responsibly On Lung Cancer Screening
2. Medical Device Developers - Network at BIOMEDevice Boston Next Week
3. Winner Medicals Special Committee Appoints Independent Financial Advisor and Retains Legal Counsel
4. Study Finds Utilizing Integrated Medical and Pharmacy Data Improves Ability to Forecast Use of High-cost Specialty Treatments
5. CareFusion to Sell Neurodiagnostic Business to Natus Medical for $58 Million
6. ulrich medical USA™ Releases New Expandable Spinal Implant for US Market
7. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
8. Essential Medical Dismisses Patent Case against Masimo and Cercacor
9. Aethlon Medical Note: An Unprecedented Data Point, The Single-Treatment Capture of Hepatitis C Virus (HCV) by the Aethlon Hemopurifier®
10. Aethlon Medical Note: Marc Robins Joins the Aethlon Team
11. Enox Biopharma, Inc. To Present Today At IN3 Medical Device 360 Conference In London
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... , January 19, 2017 ... administration appears serious about reducing the FDA,s regulatory ... innovation in the medical drug industry, many of ... with new clinical trials and development of advanced ... forging ahead with recent developments include:  Moleculin Biotech, ...
(Date:1/19/2017)... 2017  Magnetic Insight Inc., leader in magnetic ... agreement with inviCRO LLC to develop intuitive image ... based on inviCRO,s VivoQuant™ visualization and post processing ... complete MPI solution package with the Momentum MPI ... imaging in vivo. MPI is a ...
(Date:1/18/2017)... 18, 2017  EnteroMedics Inc. (NASDAQ: ... neuroblocking technology to treat obesity, metabolic diseases and ... an underwritten public offering of units for gross ... discounts and commissions and offering expenses payable by ... Class A Units, priced at a public offering ...
Breaking Medicine Technology:
(Date:1/19/2017)... ... 2017 , ... Tribble Insurance Agency, a family owned and operated firm offering ... charity event to honor Chad Phillip Dermyer, a local police trooper who was shot ... and his fellow officers were conducting routine stops of suspects when one of them, ...
(Date:1/19/2017)... ... January 19, 2017 , ... For the second consecutive year, ... Connecticut (RMACT) have earned “Top Doctor” awards. Dr. Mark Leondires, Dr. Spencer Richlin, ... been chosen by their peers for the 2017 list based on their exceptional ...
(Date:1/19/2017)... ... January 19, 2017 , ... Sales Focus Inc. (SFI), a Maryland-based sales ... market. , Over the past 20 years SFI has been recognized as the world’s ... six new clients into the US market. The new clients include: Panacea Pro, ...
(Date:1/19/2017)... ... January 19, 2017 , ... Fillers are known ... Few people know that popular cosmetic fillers can enhance earlobes and ... medical director of the MilfordMD Cosmetic Dermatology Surgery & Laser Center, in Milford, ...
(Date:1/18/2017)... ... January 18, 2017 , ... ... of Bioengineering are collaborating on a research project focused on multiple sclerosis (MS). ... seeks to use nanotechnology to control the disease without compromising normal immune function ...
Breaking Medicine News(10 mins):